Modern targeted drugs are revolutionising cancer care, yet they often increase survival by only a few months.
The new cancer maps could lead to better blood tests for diagnosing the respective cancers, as well as better targeted drugs.
But let's indulge the hopefulness for a moment and assume that we really are entering a golden age of rationally designed, targeted drugs.
Those on targeted drugs also responded for longer than those who were not (five months, as against two months, on average).
